Akari Therapeutics, Plc announced the appointment of Rachelle Jacques as Chief Executive Officer. Her appointment begins at the end of March 2022. Outgoing Chief Executive Officer, Clive Richardson, will continue to serve the Company, supporting Rachelle to accelerate business development and ensuring a smooth transition.

Before this appointment, Ms. Jacques served as Chief Executive Officer of Enzyvant Therapeutics Inc. Prior to Enzyvant, she served as the Senior Vice President and Global Complement Franchise Head at Alexion Pharmaceuticals Inc. Ms. Jacques serves on the boards of directors of uniQure N.V. and Corbus Pharmaceuticals.